| Fiscal period | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Period End Date | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 |
|---|
| Revenues: Net product sales | 12,117.20 | 5,567.60 | 4,834.40 | 4,106.20 | 3,718.50 | 3,338.40 | 2,689.48 | 1,750.76 | 1,425.84 | 858.09 |
| Revenues: Collaboration revenue: Bayer HealthCare | 1,409.30 | 1,186.10 | 1,145.60 | 1,036.10 | 938.10 | 744.30 | 580.49 | 495.56 | 220.29 | 70.10 |
| Revenues: Collaboration revenue: Sanofi-aventis | 1,902.20 | 1,186.40 | 403.60 | (125.70) | 877.20 | 658.70 | 758.87 | 541.30 | 430.11 | 423.81 |
| Revenues: Contract manufacturing | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenues: Contract research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenues: Research progress payments | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenues: Technology Licensing & Other Revenue | 281.20 | 557.00 | 174.00 | 129.00 | 338.40 | 119.00 | 74.89 | 31.94 | 28.51 | 26.47 |
| Revenues: Collaboration revenue: Roche | 361.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Revenues | 16,071.70 | 8,497.10 | 6,557.60 | 5,145.60 | 5,872.20 | 4,860.40 | 4,103.73 | 2,819.56 | 2,104.75 | 1,378.48 |
| Cost of goods sold | 1,773.10 | 491.90 | 362.30 | 180.00 | 202.50 | 194.60 | 241.70 | 129.03 | 118.05 | 83.93 |
| Cost of collaboration manufacturing | 664.40 | 628.00 | 402.80 | 237.50 | 194.60 | 105.10 | 151.01 | 75.99 | 37.31 | 0.53 |
| Gross Profit | 13,634.20 | 7,377.20 | 5,792.50 | 4,728.10 | 5,475.10 | -- | 3,711.02 | 2,614.54 | 1,949.39 | 1,294.02 |
| Research and development | 2,908.10 | 2,735.00 | 2,450.00 | 1,468.80 | 2,075.10 | 2,052.30 | 1,620.58 | 1,271.35 | 859.95 | 625.55 |
| General and Administrative | 1,824.90 | 1,346.00 | 1,341.90 | 1,127.20 | 1,320.40 | 1,177.70 | 838.53 | 519.27 | 346.39 | 210.76 |
| Other operating (income) expense, net | 45.60 | 280.40 | 209.20 | 402.30 | -- | -- | -- | -- | -- | -- |
| Total Operating Expense | 7,124.90 | 4,920.50 | 4,347.80 | 2,611.20 | 3,792.60 | 3,529.70 | 2,851.81 | 1,995.64 | 1,361.70 | 920.76 |
| Income (loss) from operations | 8,946.80 | 3,576.60 | 2,209.80 | 2,534.40 | 2,079.60 | 1,330.70 | 1,251.92 | 823.92 | 743.05 | 457.71 |
| Interest expense | 57.30 | 56.90 | 30.20 | 28.20 | 25.10 | 7.20 | 14.24 | 37.37 | 46.44 | 45.30 |
| Earnings (Loss in) from Amgen-Regeneron Partners | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Investment income | -- | -- | -- | -- | -- | -- | -- | -- | (0.23) | 2.01 |
| Other contract income | 436.30 | 290.70 | 249.50 | 47.30 | 24.00 | 6.30 | (12.58) | (25.31) | -- | -- |
| Gain (Loss) on early extinguishment of debt | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other income (expense) | 379.00 | 233.80 | 219.30 | 19.10 | (1.10) | (0.90) | (26.82) | (62.68) | (46.67) | (43.29) |
| Pre-Tax Income | 9,325.80 | 3,810.40 | 2,429.10 | 2,553.50 | 2,078.50 | 1,329.80 | 1,225.10 | 761.24 | 696.38 | 414.42 |
| Income tax expense (benefit) | 1,250.50 | 297.20 | 313.30 | 109.10 | 880.00 | 434.30 | 589.04 | 423.11 | 282.64 | (335.85) |
| Current - Federal | 1,429.80 | 199.00 | 444.60 | 223.70 | 560.30 | 787.00 | -- | -- | -- | -- |
| Deferred - Federal | (423.20) | 109.00 | (132.00) | 687.60 | 317.10 | (377.40) | -- | -- | -- | -- |
| Current - foreign | (38.40) | 21.40 | (2.60) | 20.60 | 4.80 | (1.40) | -- | -- | -- | -- |
| Current - State | 6.20 | 1.20 | 1.90 | 4.80 | (4.10) | 8.80 | -- | -- | -- | -- |
| Deferred - foreign | 276.70 | (31.40) | 3.10 | (825.70) | 3.20 | 3.90 | -- | -- | -- | -- |
| Deferred - state | (0.60) | (2.00) | (1.70) | (1.90) | (1.30) | 13.40 | -- | -- | -- | -- |
| Net income (loss) before cumulative effect of a change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of adopting Statement of Financial Accounting Standards | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net income attributable to common shareholders | 8,075.30 | 3,513.20 | 2,115.80 | 2,444.40 | 1,198.50 | 895.50 | 636.06 | 338.13 | 413.74 | 750.27 |
| Continuing Operations- (Basic) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of adopting | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Basic) | 76.40 | 32.65 | 19.38 | 22.65 | 11.27 | 8.55 | 6.17 | 3.36 | 4.23 | 7.92 |
| Continuing Operations- (Diluted) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of adopting SAB101 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Diluted) | 71.97 | 30.52 | 18.46 | 21.29 | 10.34 | 7.70 | 5.52 | 2.98 | 3.72 | 6.75 |
| Weighted Average Shares Outstanding (Basic) | 105.70 | 107.60 | 109.20 | 107.90 | 106.30 | 104.70 | 103.06 | 100.61 | 97.92 | 94.69 |
| Weighted Average Shares Outstanding (Diluted) | 112.20 | 115.10 | 114.60 | 114.80 | 115.90 | 116.30 | 115.23 | 113.41 | 111.29 | 115.38 |